Eye - subfoveal choroidal neovascularisation

The PBS subsidises aflibercept, brolucizumab and ranibizumab for patients with subfoveal choroidal neovascularisation (CNV).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with aflibercept, brolucizumab and ranibizumab under the National Health Act 1953, Section 85 for patients with subfoveal CNV.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, brolucizumab and ranibizumab.

Treatment specifics

To be eligible for PBS subsidised treatment with aflibercept, brolucizumab and ranibizumab, patients must be treated by:

  • an ophthalmologist
  • an accredited ophthalmology registrar in consultation with an ophthalmologist.

Authority applications

Applying for initial treatment

Apply for initial authority approval to prescribe PBS subsidised aflibercept, brolucizumab or ranibizumab to treat CNV in writing and either:

All written applications must include the completed:

Applications to move between different drugs to treat CNV will require a new initial authority application to be completed.

Applying for initial grandfather treatment

For patients who received non-PBS subsidised brolucizumab treatment for CNV before 1 October 2021, apply for initial grandfather approval in writing and either:

  • upload through HPOS
  • post to PBS Complex Drugs Programs.

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised aflibercept, brolucizumab or ranibizumab to treat CNV can be made either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 3 March 2022